Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Delgocitinib cream twice-daily may lead to clinically significant improvements in health-related quality of life (HRQoL) among individuals with 

These recent findings resulted from the phase 3 DELTA 1 (NCT04871711) and DELTA 2 (NCT04872101) studies. Andrea Bauer, MD, MPH, of the University Hospital Carl Gustav Carus in Dresden, Germany, led a team of other investigators in authoring these data.

The phase 3 clinical trials DELTA 1 and DELTA 2 had been conducted using identical study designs to look into the efficacy of delgocitinib cream in adults with moderate-to-severe CHE. Bauer et al described the previous results of delogocitinib for CHE in the DELTA trial program before highlighting the latest assessment of the findings from these 2 studies.

“In two pivotal randomised, double-blind, multicentre phase 3 trials…twice-daily application of delgocitinib cream 20 mg/g resulted in superior efficacy versus cream vehicle and was well-tolerated over 16 weeks,” the investigators wrote.

 “Here, we report the effects of delgocitinib cream 20 mg/g versus cream vehicle on HRQoL in data pooled from the DELTA 1 and DELTA 2 trials.”

Those deemed eligible for inclusion in the DELTA trials had a score of 3 (moderate) or 4 (severe) on a modified Investigator’s Global Assessment for Chronic Hand Eczema (IGA-CHE). They were then randomly assigned in a 2:1 ratio to be treated either with delgocitinib cream 20 mg/g or a vehicle cream, applied twice each day for a total of 16 weeks under double-blind conditions.  Outcomes related to HRQoL were assessed via several different patient-reported outcome measures.

Such measures included the Dermatology Life Quality Index (DLQI), the EQ-5D-5L questionnaire and its visual analogue scale (EQ VAS), and the Hand Eczema Impact Scale (HEIS). Additional HEIS components assessed Bauer and colleagues included the Proximal Daily Activity Limitations (PDAL) and Embarrassment (Emb) subscores. The EQ-5D-5L instrument was descibed as a preference-based, generic measure designed to capture an individual’s health status across 5 dimensions: self-care, mobility, usual activities, pain or discomfort, and anxiety or depression. Responses lead to a utility score anchored between 1, representing perfect health, and 0, representing death.

For their analysis, the investigative team pooled patient data from both of the DELTA studies and compared any shifts from the point of baseline in EQ-5D, DLQI, and HEIS outcomes, including the PDAL and Emb subsets. Across the pair of trials, there were 639 participants randomized to treatment with delgocitinib cream, whereas 321 were placed on the vehicle comparator.

At 16-week mark, delgocitinib cream use was linked with significantly greater improvements in HRQoL measures compared with the vehicle cream. Specifically, Bauer and coauthors noted statistically significant differences favoring delgocitinib for DLQI scores, EQ-5D scores, overall HEIS scores, as well as the HEIS PDAL and HEIS Emb subscores. All comparisons reached 

Additionally, the investigative team found greater proportions of subjects in the delgocitinib arm attained clinically meaningful improvements in these patient-reported outcomes relative to those on the vehicle (all 

 < .001). The analysis also suggested individuals given delgocitinib spent a longer average duration in an improved HRQoL state during the study period.

Overall, Bauer et al concluded the use of twice-daily delgocitinib cream 20 mg/g produced clinically meaningful and statistically significant improvements in life quality outcomes versus the vehicle control across all patient-reported measures. Any distinctions between treatment arms emerged rapidly, with benefits favoring delgocitinib evident as early as the first week and increasing steadily throughout the 16-week treatment period.

“Given that HEIS was specifically developed to assess HRQoL in patients with CHE, it may have greater utility in clinical trials in CHE than more generic tools,” they concluded.

 “However, both EQ-5D and DLQI were also shown to correlate with clinical improvement, and all three measures should be considered complementary.”

Several limitations were acknowledged by the team when interpreting these findings, however, including the racial makeup of the trial population, consisting predominantly of White participants. This, Bauer and colleagues noted, may limit the generalizability of data to more diverse racial and ethnic groups. The treatment duration was also limited to 16 weeks, so the investigators pointed to ongoing research as necessary to evaluatw longer-term outcomes. Ongoing research included assessing the impact of delgocitinib cream on HRQoL up to 52 weeks in the DELTA 3 study.

Bauer A, Guenther L, Woolf R, et al. Effect of Delgocitinib Cream on Health-Related Quality of Life in Patients With Moderate to Severe Chronic Hand Eczema. Contact Dermatitis (2026): 1–9. 

Bissonnette R, Warren RB, Schliemann S, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials. Lancet. 2024 Aug 3;404(10451):461-473. doi: 10.1016/S0140-6736(24)01027-4. Epub 2024 Jul 18. PMID: 39033766.

Articles

Twice-daily delgocitinib cream 20 mg/g demonstrated clinically meaningful, statistically significant improvements in health-related quality of life for adults with moderate-to-severe chronic hand eczema over 16 weeks. Pooled phase 3 DELTA 1/2 data showed consistent benefits versus vehicle across dermatology-specific, generic, and hand eczema–specific PRO instruments, with separation emerging by week 1 and increasing through week 16. Improvements extended to daily activity limitations and embarrassment domains, and patients spent longer in improved HRQoL states. Generalizability and durability remain key considerations.

Twice-daily delgocitinib cream 20 mg/g in those with moderate to severe chronic hand eczema led to significant HRQoL improvements.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

DELTA: Delgocitinib Cream Improves Health-Related Quality of Life in CHE

Professor of Immunology and Allergy at Imperial College London and 
European Academy of Allergy and Clinical Immunology (EAACI) Secretary General

PQ Grass: Convenient Symptom Relief in Seasonal Allergic Rhinitis, With Mohamed Shamji, PhD

PQ Grass: Convenient Symptom Relief in Seasonal Allergic Rhinitis, With Mohamed Shamji, MD

PQ Grass 27600 SU, a chemically modified allergen preparation delivering just 6 subcutaneous injections pre-seasonally has demonstrated both clinically meaningful symptom reduction and broad immune tolerance induction according to new data presented at the 

American Academy of Allergy, Asthma & Immunology (AAAAI)

 2026 Annual Meeting held in Philadelphia, Pennsylvania, by Mohamed Shamji, PhD, Professor of Immunology and Allergy at Imperial College London and secretary general at European Academy of Allergy and Clinical Immunology.

The data come from pooled analyses across 2 clinical trials, PQG309 and PQG306, evaluating PQ Grass 27,600 SU (a polymerized, chemically modified extract of 13 grass species) in patients with seasonal allergic rhinitis, with or without asthma (n = 75; PQ Grass, n = 40; placebo, n = 35). To discuss the findings and their implications for the future of allergen immunotherapy, we sat down with Shamji during the meeting to learn more about the clinical meaningfulness of the study findings. The study yielded a 22.5% improvement (

 <.00004) in the Combined Symptom Medication Score over placebo in a large AIT trial, its primary end point, atop a placebo response that itself commonly reaches 50%, meaning patients are experiencing roughly a 74% total reduction in symptoms — from 6 injections, with a adherence burden that bears no comparison to the 60-clinic-visit commitment of conventional 3-year subcutaneous or daily sublingual immunotherapy.

Mechanistically, PQ Grass induced robust systemic increases in grass pollen-specific blocking antibodies — sIgG (

 <.01) compared to placebo, measured both pre- and post-pollen season. Functionally, serum from treated patients significantly inhibited allergen-IgE complex binding to B cells pre-season (

 <.01). At the cellular level, PQ Grass suppressed proliferation of both Th2 (

 <.05) effector subsets, with trends toward reduced Tfh and IL-21+ Tfh cell proliferation and a positive trend in memory Treg induction — together painting a tolerogenic profile consistent with sustained clinical benefit and supporting PQ Grass as a viable accelerated-course alternative to conventional immunotherapy schedules.

“Patients only have 6 shots, and they really feel better. They have reduced symptoms during the pollen season. They take less risky medications like antihistamine or nasal steroids. And I think that's very important and very meaningful for the patients,” Shamji said.

Shamji’s disclosure information was not available. 

Layhadi J, Starchenka S, de Kam PJ, et al. PQ Grass 27600 SU effectively induces tolerogenic properties through modulation of humoral and cellular immune responses for the treatment of seasonal allergic rhinitis. Presented at: AAAAI 2026 Annual Meeting, February 27-March 2, Philadelphia, Pennsylvania. Abstract #L77

Videos

Shamji discussed the advantages of PQ grass over conventional immunotherapy at AAAAI 2026.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Douglas P. Mack, a pediatric allergist and assistant clinical professor at McMaster University

 Intranasal Epinephrine Preferred by 88% Over Auto-Injectors, With Douglas Mack, MD

 Annual Meeting 2026 in Philadelphia suggest that patients and caregivers overwhelmingly prefer a needle-free intranasal epinephrine device over traditional auto-injectors for the treatment of 

In a randomized crossover study of 90 participants, 88% preferred the intranasal epinephrine product EURneffy over standard epinephrine auto-injectors. The findings, presented as late-breaking data at the meeting, indicate that device design and usability may play a significant role in whether patients consistently carry and administer epinephrine during severe allergic reactions.

 lead author Douglas P. Mack, a pediatric allergist and assistant clinical professor at McMaster University, said the primary objective of the study was to evaluate user preference between the 2 treatment modalities and better understand what factors drive those preferences. Results showed a strong overall preference for the intranasal option, with nearly 9 in 10 participants selecting it over injectable devices. The team also wanted to see how participants would perform with and without training.

“What was cool with the study is that we had not only patients who had a history of allergy, we had caregivers, we had children, but we also had naive patients who…had no experience whatsoever with auto injectors or with food allergy or any type of allergies,” Mack said. “These were people who had no experience whatsoever. We did absolutely see that almost everybody who was naïve had a preference for the epinephrine auto-injector for the intranasal epinephrine. We still did have about 8% of the population who prefer the epinephrine auto-injection.”

These findings indicate that device familiarity did not impact patient preference. Rather, usability advantages may be particularly meaningful for newly diagnosed patients or those encountering epinephrine therapy for the first time.

Investigators also assessed practical barriers that often limit real-world epinephrine use. Prior research has shown that many individuals prescribed epinephrine do not consistently carry their devices and may hesitate to administer them during an anaphylactic emergency.

According to Mack, several factors, including device size, portability, needle aversion, and concerns about bystander administration, can contribute to these barriers. In the study, participants rated the intranasal device more favorably across multiple usability domains, including ease of carrying, ease of use, and reduced anxiety associated with needle injections.

“I think this is going to hopefully open the door to even further research into…a setting where there [are] no training or [usage] as a stock epinephrine. Our goal is to get this into the patient… having a device that's simple to use, easy to carry, is really what we're looking for. Now, there's always [going to] be people who will still use the auto injector. There's no question. But I think [intranasal epinephrine] provides a choice for families and a choice for patients.”

New data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors. BioSpace. Published March 4, 2026. Accessed March 5, 2026. 

https://www.biospace.com/press-releases/new-data-reveals-9-in-10-people-prefer-eurneffy-a-needle-free-nasal-adrenaline-spray-over-auto-injectors

A randomized crossover study shows that most patients prefer intranasal epinephrine for anaphylaxis due to its ease of use, portability, and the absence of needles.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Intranasal Epinephrine Preferred by 88% Over Auto-Injectors, With Douglas Mack, MD

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

ACHIEVE-3: Orforglipron Demonstrates Superiority to Semaglutide in Poorly Controlled T2D

Eli Lilly’s investigational once-daily GLP-1 receptor agonist orforglipron has outperformed oral semaglutide 7 and 14 mg in patients with type 2 diabetes inadequately controlled with metformin. Over 52 weeks, orforglipron resulted in superior improvements in weight and A1C, demonstrating superiority over the primary and all key secondary endpoints. Notably, orforglipron exhibits no food or water restrictions, setting it apart from existing oral GLP-1s.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the results of ACHIEVE-3 and the promise of orforglipron as an oral GLP-1 with no dietary restrictions.

Check out the full episode on recent GLP-1 trials and results 

In this segment, Isaacs and Bellini discuss the recently published results of the ACHIEVE-3 Trial, a phase 3 study evaluating the investigational oral GLP-1 receptor agonist Orforglipron. Unlike peptide-based GLP-1 therapies, orforglipron is a non-peptide molecule that does not require fasting administration and can be taken alongside food, beverages, and other medications, potentially improving convenience and adherence compared with Semaglutide in its oral form.

The hosts review the head-to-head trial, which enrolled 1,698 patients with type 2 diabetes already taking metformin and compared two doses of orforglipron (12 mg and 36 mg) with oral semaglutide (7 mg and 14 mg). Results showed greater glycemic reductions with orforglipron, with mean A1C decreases of approximately 1.7% and 1.9% for the two doses, compared with reductions of 1.2% and 1.5% with semaglutide. All primary noninferiority comparisons were met, and the investigational agent demonstrated statistical superiority in A1C lowering.

The conversation then turns to tolerability. Gastrointestinal adverse events were reported more frequently with orforglipron, affecting roughly 58–59% of participants compared with 37–45% among those receiving semaglutide. The hosts discuss the nuances of adverse-event reporting in clinical trials, noting that even a single episode of nausea may be recorded as an event, which can inflate incidence rates. Despite higher rates of GI symptoms, discontinuation due to these effects remained relatively low, occurring in approximately 6% of patients receiving orforglipron compared with 3% with semaglutide, suggesting that most patients were able to continue therapy.

The panel highlights the potential clinical implications of these findings. The greater glucose-lowering efficacy may reflect the drug’s potency, but clinicians will need more information on dose-titration strategies and the duration of GI side effects to determine real-world tolerability. They also note that the comparison did not include the highest available dose of semaglutide, representing a limitation when interpreting relative efficacy.

Looking ahead, the hosts discuss the regulatory outlook for orforglipron, which has reportedly been submitted to regulators in more than 40 countries, including the United States, with initial approval efforts focused on obesity. They also emphasize the importance of cardiovascular outcomes data, which are currently available for semaglutide through large trials but not yet for orforglipron, which will likely play a critical role in determining how the therapies are positioned in clinical practice.

The discussion concludes with cautious optimism about expanding oral GLP-1 options. While the convenience and potency of orforglipron are promising, the hosts stress the importance of established cardiovascular evidence when selecting therapies for patients with diabetes and obesity who are at elevated cardiovascular risk.

Editor’s Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Eli Lilly. Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet. February 26, 2026. Accessed March 5, 2026. 

https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-delivered-superior-blood-sugar

Rosenstock J, Yabe D, Cox D, et al. Efficacy and safety of once-daily oral Orforglipron compared with oral semaglutide in adults with type 2 diabetes (achieve-3): A multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. The Lancet. Published online February 26, 2026. 

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover the recently published trial results and what they mean for Eli Lilly’s newest GLP-1 molecule.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Stefani Tica, MD, MPH, is an assistant professor of pediatrics in the Division of Gastroenterology, Hepatology, and Nutrition at Washington University School of Medicine in St Louis.

When Does MASLD Risk Begin? New Research on Early-Life Factors

As rates of metabolic dysfunction-associated steatotic liver disease (MASLD) continue to rise, experts are increasingly examining how risk for metabolic disease may develop earlier in life than previously recognized, with emerging evidence suggesting that factors shaping MASLD risk may extend beyond an individual’s current metabolic health to include early-life exposures and parental health.

A new analysis of data from the UK Avon Longitudinal Study of Parents and Children (ALSPAC) offers additional insight into how risk for MASLD may begin far earlier in life than previously recognized, potentially even before a child is born. In an interview discussing the study, study author Stefani Tica, MD, MPH, an assistant professor of pediatrics in the Division of Gastroenterology, Hepatology, and Nutrition at Washington University School of Medicine in St Louis, explained that the work was motivated by the complex and multifactorial nature of metabolic disease.

“One of the things that I always counsel my MASLD patients about is that usually problems with our metabolism are really complex, and there's no one single thing that has gone awry,” Tica said. “One of the inspirations for this project was really kind of leaning into these complex interactions with not only what we're eating or how we're using these energy stores, but also our genetics, our environment, stress, kind of the realities of our life.”

The study approached MASLD through a population health lens, aiming to better understand how early-life and family-level factors might shape long-term risk. Rising MASLD incidence across both pediatric and adult populations prompted the team to look beyond individual health markers at the time of diagnosis and instead consider a broader life-course perspective.

In pediatric populations, recent research examining National Health and Nutrition Examination Survey (NHANES) 2011-2020 data estimated the overall prevalence of suspected MASLD in the adolescent population was 11.3%.

In the present study, investigators included 1933 offspring from the ALSPAC to assess the associations between parental pre-pregnancy BMI and odds of offspring MASLD at age 24 years, with MASLD defined as hepatic steatosis on transient elastography and ≥1 cardiometabolic risk factors.

Results showed that at age 24 years, 10.4% of offspring had MASLD. Pre-pregnancy maternal and paternal obesity were independently associated with an increased odds of offspring MASLD, with each 1 kg/m2 increase in maternal BMI increasing the odds of MASLD by 10% (odds ratio [OR], 1.10; 95% CI, 1.06 to 1.14), while each 1 kg/m2 increase in paternal BMI raised the odds by 9% (OR, 1.09; 95% CI, 1.04 to 1.13).

Further analysis revealed biparental overweight or obesity was associated with 3.73 times the odds of offspring MASLD (OR, 3.73; 95% CI, 2.43 to 5.73) compared with parents with a normal BMI, with 67% of this association mediated by cumulative excess childhood BMI.

For clinicians, particularly pediatric hepatologists and pediatric providers, these findings underscore the importance of earlier conversations about metabolic risk. Tica noted that framing these discussions around family health and long-term outcomes may help engage both children and parents in preventive efforts.

“I think this is quite interesting in the sense that it's not necessarily the person who we're seeing right then and there and what their BMI is and what their other metabolic health markers are looking like, but that sort of risk for disease might develop much earlier on,” Tica explained. “I think having this more longitudinal life course perspective on it reinvigorates efforts from a public health standpoint to intervene earlier on in life and potentially have a much bigger impact if you can successfully do that.”

She also noted that the research raises several important unanswered questions. As an observational study, it cannot establish the biological mechanisms underlying these associations. However, emerging preclinical evidence suggests potential roles for epigenetic changes and alterations in the gut microbiome, particularly in infants exposed to maternal obesity or dietary differences during early development.

According to Tica, further mechanistic research will be essential to determine whether interventions, such as parental weight loss or metabolic improvements, can meaningfully alter MASLD risk in future generations.

Editor’s note: Tica reports no relevant disclosures.

Tica S, Luo C, Ren D, et al. Parental obesity and risk of metabolic dysfunction associated steatotic liver disease in adult offspring: UK birth cohort study. 

. Published online February 24, 2026. doi:10.1136/gutjnl-2025-336165

Brooks A. Up to 11% of US Adolescents Have Suspected MASLD, Study Finds. HCPLive. February 17, 2025. Accessed March 5, 2026. 

https://www.hcplive.com/view/an-estimated-11-us-adolescents-have-suspected-masld-study-finds

New research suggests MASLD risk may develop early in life, highlighting the impact of parental factors and cumulative childhood adiposity.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Understanding Intergenerational Risk Factors for MASLD, With Stefani Tica, MD, MPH

Adam DeVore, MD, MHS, is an associate professor of medicine in the division of cardiology at the Duke University School of Medicine and medical director of the Duke Heart Transplant program.

In the final part of this 6-part HCPLive Special Report, experts discuss the recently released HFSA/AAHFN joint statement on tech integration in heart failure care.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

How AI Can Help Heart Failure Care

In part 5 of this 6-part HCPLive Special Report, experts discuss the recently released HFSA/AAHFN joint statement on tech integration in heart failure care.

What Needs to Change in the Face of New Tech in Heart Failure

In part 4 of this 6-part HCPLive Special Report, experts discuss the recently released HFSA/AAHFN joint statement on tech integration in heart failure care.

Interdisciplinary Integration in Heart Failure

In part 3 of this 6-part HCPLive Special Report, experts discuss the recently released HFSA/AAHFN joint statement on tech integration in heart failure care.

Bridging Trials and Clinical Practice in Heart Failure

In part 2 of this 6-part HCPLive Special Report, experts discuss the recently released HFSA/AAHFN joint statement on tech integration in heart failure care.

Adapting to the Pace of Tech Implementation in Heart Failure

In part 1 of this 6-part HCPLive Special Report, experts discuss the recently released HFSA/AAHFN joint statement on tech integration in heart failure care.

Why Tech Integration Matters in Heart Failure

Sayantani Sindher, MD, is a clinical associate professor at the Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine.

COMBINE trial data show dupilumab added to omalizumab-assisted OIT improved desensitization and reduced GI symptoms, despite no sustained response benefit.


Food Allergy

Dupilumab Reduces GI Symptoms During Multi-Allergen OIT, With Sayantani Sindher, MD

Sayna Norouzi, MD, is an assistant professor of medicine and clinical nephrologist at Loma Linda University Medical Center

FDA-approved iptacopan and pegcetacoplan offer new complement-targeted therapies for C3 glomerulopathy.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

C3 Glomerulopathy

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.

Complement Inhibitors Reshape Treatment Landscape for C3 Glomerulopathy, With Sayna Norouzi

This segment of the latest episode of The Medical Sisterhood podcast highlights the value of a supportive partner among those who are physician parents.

How Important is a Supportive Spouse as a Physician Mother?

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Podcasts

Hosts are joined by Su Wang, MD, MPH, to discuss the evolving management of hepatitis B and how to move care beyond silos with expanded treatment and provider empowerment.

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Liver Lineup: Updates & Unfiltered Insights

Introducing Liver Lineup: Updates & Unfiltered Insights — an exciting new podcast delivering timely, candid perspectives on the most pressing topics in the fast-moving world of hepatology. Created by Nancy Reau, MD, and Kimberly Brown, MD, and hosted by HCPLive, this series dives into the cutting edge of liver disease research, clinical care, and real-world practice.

Latest News

DELTA: Delgocitinib Cream Improves Health-Related Quality of Life in CHE

PQ Grass: Convenient Symptom Relief in Seasonal Allergic Rhinitis, With Mohamed Shamji, PhD

Intranasal Epinephrine Preferred by 88% Over Auto-Injectors, With Douglas Mack, MD

ACHIEVE-3: Orforglipron Demonstrates Superiority to Semaglutide in Poorly Controlled T2D

Understanding Intergenerational Risk Factors for MASLD, With Stefani Tica, MD, MPH